Drug Profile
NVP QAB 205
Alternative Names: NVP-QAB205; NVP-QAB205AALatest Information Update: 19 Jul 2010
Price :
$50
*
At a glance
- Originator Novartis
- Class Antiasthmatics; Bronchodilators; Small molecules
- Mechanism of Action Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 19 Jul 2010 Discontinued - Preclinical for Asthma in Switzerland (unspecified route)
- 19 Jul 2010 Discontinued - Preclinical for Asthma in United Kingdom (unspecified route)
- 20 Sep 2002 Preclinical trials in Asthma in United Kingdom (unspecified route)